Beta Bionics (NASDAQ:BBNX) Upgraded to Strong-Buy at Leerink Partnrs

Beta Bionics (NASDAQ:BBNX) was upgraded by investment analysts at Leerink Partnrs to a “strong-buy” rating in a report issued on Monday,Zacks.com reports.

Several other equities research analysts have also commented on the company. Stifel Nicolaus assumed coverage on Beta Bionics in a research note on Monday. They set a “buy” rating and a $25.00 price objective for the company. Leerink Partners started coverage on shares of Beta Bionics in a research note on Monday. They issued an “outperform” rating and a $28.00 price target on the stock. LADENBURG THALM/SH SH began coverage on shares of Beta Bionics in a research report on Thursday, February 20th. They set a “neutral” rating and a $20.00 price objective for the company. Piper Sandler began coverage on Beta Bionics in a research note on Monday. They set an “overweight” rating and a $26.00 price target on the stock. Finally, Baird R W upgraded Beta Bionics to a “hold” rating in a research report on Thursday, February 20th. Three investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $24.83.

Beta Bionics Stock Up 0.1 %

Shares of NASDAQ BBNX opened at $20.60 on Monday. Beta Bionics has a 52 week low of $20.00 and a 52 week high of $24.50.

Insider Buying and Selling at Beta Bionics

In other news, insider Mike Mensinger purchased 33,350 shares of the firm’s stock in a transaction that occurred on Friday, January 31st. The stock was bought at an average price of $17.00 per share, for a total transaction of $566,950.00. Following the completion of the purchase, the insider now directly owns 59,019 shares of the company’s stock, valued at $1,003,323. The trade was a 129.92 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, major shareholder Hadley Harbor Aggre Wellington purchased 1,000,000 shares of the stock in a transaction on Friday, January 31st. The shares were purchased at an average price of $17.00 per share, with a total value of $17,000,000.00. Following the acquisition, the insider now directly owns 3,901,599 shares in the company, valued at $66,327,183. This represents a 34.46 % increase in their ownership of the stock. The disclosure for this purchase can be found here.

Beta Bionics Company Profile

Beta Bionics, Inc is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.